Utilized for benign prostatic hyperplasia to manage prostate volume and support urinary health.
Mechanism of Action
Dutasteride inhibits both Type I and Type II isoforms of 5-alpha reductase. This reduces the conversion of testosterone to dihydrotestosterone, the hormone responsible for the growth of the prostate and male pattern hair loss.
Route of Administration
Oral
Onset Time
3–6 months
Duration
3–5 weeks (half-life)
Contraindications
Pregnancy, Use in females, Use in children, Hypersensitivity to dutasteride
Severe Adverse Events
Prostate cancer (high-grade), Male breast cancer, Angioedema — requires immediate medical attention
Information related to Dutasteride is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
